期刊
FASEB JOURNAL
卷 36, 期 1, 页码 -出版社
WILEY
DOI: 10.1096/fj.202101085RR
关键词
age-related macular degeneration; angiogenic factor; anti-angiogenic therapy; choroidal neovascularization; secretogranin III
资金
- NIII [Y027749, R24EY028764, R24EY02876401A1S1, R43FY031238, R43FY031643, R43EY032827, R41 EY027665]
- American Diabetes Association [1 -18 -IBS -172]
- NIH [P30EY002520, P30EY014801]
- Knights Templar Eye Foundation Endowment in Ophthalmology
- Research to Prevent Blindness (RPB)
Choroidal neovascularization (CNV), a leading cause of blindness in the elderly, is commonly treated with vascular endothelial growth factor (VEGF) inhibitors, but these therapies have limited efficacy and potential side effects. This study explores the potential of secretogranin III (Scg3) as a disease-selective angiogenic factor for the treatment of CNV. The researchers found that Scg3 binds specifically to CNV vessels and its neutralization inhibits CNV. The combination of an anti-Scg3 antibody and a VEGF inhibitor showed synergistic effects in alleviating CNV. These findings suggest that Scg3 could be a next-generation targeted therapy for CNV.
Choroidal neovascularization (CNV), a leading cause of blindness in the elderly, is routinely treated with vascular endothelial growth factor (VEGF) inhibitors that have limited efficacy and potentially adverse side effects. An unmet clinical need is to develop novel therapies against other angiogenic factors for alternative or combination treatment to improve efficacy and safety. We recently described secretogranin III (Scg3) as a disease-selective angiogenic factor, causally linked to diabetic retinopathy and acting independently of the VEGF pathway. An important question is whether such a disease-selective Scg3 pathway contributes to other states of pathological angiogenesis beyond diabetic retinopathy. By applying a novel in vivo endothelial ligand binding assay, we found that the binding of Scg3 to CNV vessels in live mice was markedly increased over background binding to healthy choriocapillaris and blocked by an Scg3-neutralizing antibody, whereas VEGF showed no such differential binding. Intravitreal injection of anti-Scg3 humanized antibody Fab (hFab) inhibited Matrigel-induced CNV with similar efficacy to the anti-VEGF drug aflibercept. Importantly, a combination of anti-Scg3 hFab and aflibercept synergistically alleviated CNV. Homozygous deletion of the Scg3 gene markedly reduced CNV severity and abolished the therapeutic activity of anti-Scg3 hFab, but not aflibercept, suggesting a role for Scg3 in VEGF-independent CNV pathogenesis and therapy. Our work demonstrates the stringent disease selectivity of Scg3 binding and positions anti-Scg3 hFab as a next-generation disease-targeted anti-angiogenic therapy for CNV.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据